EOFLOW Co.,Ltd. Stock

Equities

A294090

KR7294090006

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
4,245 KRW +3.16% Intraday chart for EOFLOW Co.,Ltd. -1.51% +1.68%

Financials

Sales 2022 6.71B 4.84M 6.66M Sales 2023 6.59B 4.76M 6.54M Capitalization 127B 91.69M 126M
Net income 2022 -30.71B -22.17M -30.5M Net income 2023 -61.94B -44.72M -61.5M EV / Sales 2022 62.1 x
Net cash position 2022 38.12B 27.52M 37.85M Net cash position 2023 2.15B 1.55M 2.13M EV / Sales 2023 18.9 x
P/E ratio 2022
-14.6 x
P/E ratio 2023
-2.05 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.07%
More Fundamentals * Assessed data
Dynamic Chart
EOFLOW Co.,Ltd. announced that it has received KRW 17 billion in funding from DB Financial Investment Co., Ltd., Samsung Securities Co., Ltd., NH Investment & Securities Co., Ltd., Tiger Investment Advisory Co.,Ltd., Hana Investment Banking & Securities Inc., Investment Arm CI
EOFLOW Co.,Ltd. cancelled the transaction announced on May 25, 2023 CI
Medtronic Korea Holdings Co., Ltd. cancelled the acquisition of 18.54% stake in EOFLOW Co.,Ltd. from Jaejin Kim. CI
US-based Medtronic Acquires EOFlow MT
Eoflow to Raise 314.9 Billion Won via Shares Issuance MT
Medtronic Korea Holdings Co., Ltd. agreed to acquire a 18.54% stake in EOFLOW Co.,Ltd. from Jaejin Kim for approximately KRW 170 billion. CI
EOFLOW Co.,Ltd. announced that it expects to receive KRW 314.903773785 billion in funding from Medtronic Korea Holdings Co., Ltd. CI
Pharmeo Inc. announced that it has received KRW 12.9999435 billion in funding from EOFLOW Co.,Ltd. CI
Pharmeo Inc. announced that it expects to receive KRW 12.9999435 billion in funding from EOFLOW Co.,Ltd. CI
EOFLOW Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
EOFLOW Co.,Ltd. announced that it has received KRW 32 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd, investment arm, Kiwoom Securities Co., Ltd., Investment Arm, SUSUNG ASSET MANAGEMENT Co., Ltd. CI
EOFLOW Co.,Ltd. announced that it expects to receive KRW 32 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd, investment arm, Kiwoom Securities Co., Ltd., Investment Arm, SUSUNG ASSET MANAGEMENT Co., Ltd. CI
Pharmeo Inc. announced that it has received KRW 9.9078 billion in funding from EOFLOW Co.,Ltd. CI
Pharmeo Inc. announced that it expects to receive KRW 9.9078 billion in funding from EOFLOW Co.,Ltd. CI
Diabeloop and EOFLOW Co.,Ltd. Partners to Offer Wearable Aid with Smartphone App CI
More news
1 day+3.16%
1 week-1.51%
Current month-7.31%
1 month-7.31%
3 months+19.75%
6 months-80.44%
Current year+1.68%
More quotes
1 week
3 750.00
Extreme 3750
4 405.00
1 month
3 470.00
Extreme 3470
4 750.00
Current year
3 335.00
Extreme 3335
6 490.00
1 year
3 335.00
Extreme 3335
29 150.00
3 years
3 335.00
Extreme 3335
34 500.00
5 years
3 335.00
Extreme 3335
42 150.00
10 years
3 335.00
Extreme 3335
42 150.00
More quotes
Managers TitleAgeSince
Founder 62 -
President 61 17-10-16
Chief Tech/Sci/R&D Officer 62 18-08-31
Members of the board TitleAgeSince
Founder 62 -
Director/Board Member 65 -
Director/Board Member 60 -
More insiders
Date Price Change Volume
24-04-29 4,245 +3.16% 329 340
24-04-29 4,115 +1.73% 97,234
24-04-26 4,045 +0.50% 304,301
24-04-25 4,025 -5.96% 254,728
24-04-24 4,280 -0.93% 204,238

End-of-day quote Korea S.E., April 29, 2024

More quotes
EOFlow Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of medical devices. The Company's main products include wearable insulin pumps, insulin infusion regulators for blood sugar control in diabetic patients.
More about the company
  1. Stock Market
  2. Equities
  3. A294090 Stock